Matorras et al., 1998 - Google Patents
Endometriosis and spontaneous abortion rate: a cohort study in infertile womenMatorras et al., 1998
View PDF- Document ID
- 12004698787682825171
- Author
- Matorras R
- Rodrı́guez F
- de Terán G
- Pijoan J
- Ramón O
- Rodrı́guez-Escudero F
- Publication year
- Publication venue
- European Journal of Obstetrics & Gynecology and Reproductive Biology
External Links
Snippet
Objective: To ascertain if there is an association between endometriosis and spontaneous abortion. Design: Prospective cohort study. Setting: Medical School Hospital. Population: 174 infertile women laparoscopically diagnosed with endometriosis and 174 infertile women …
- 201000009273 endometriosis 0 title abstract description 101
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matorras et al. | Endometriosis and spontaneous abortion rate: a cohort study in infertile women | |
| da Fonseca et al. | Preterm birth prevention | |
| AAGL Elevating Gynecologic Surgery j. abbott@ unsw. edu. au | AAGL practice report: practice guidelines on intrauterine adhesions developed in collaboration with the European Society of Gynaecological Endoscopy (ESGE) | |
| Raziel et al. | Ovarian pregnancy—a 12-year experience of 19 cases in one institution | |
| Lang et al. | Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study | |
| Naoulou et al. | Efficacy of tranexamic acid in the treatment of idiopathic and non‐functional heavy menstrual bleeding: a systematic review | |
| Westhoff et al. | Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women | |
| Taniguchi et al. | Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma | |
| Bhandari et al. | Reproductive outcome of patients with Asherman’s syndrome: a SAIMS experience | |
| Farquhar et al. | An evidence‐based guideline for the management of uterine fibroids | |
| Hidalgo et al. | Ovarian cysts in users of Implanon® and Jadelle® subdermal contraceptive implants | |
| Cheng | Medical abortion in early pregnancy: experience in China | |
| Dason et al. | Guideline No. 437: diagnosis and management of adenomyosis | |
| Matorras et al. | Women who are not exposed to spermatozoa and infertile women have similar rates of stage I endometriosis | |
| Long et al. | Reoperation and pain-related outcomes after hysterectomy for endometriosis by oophorectomy status | |
| Lemmers et al. | MisoREST: Surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: A cohort study | |
| Elford et al. | Novel treatment of a patient with secondary infertility due to retained fetal bone | |
| Matalliotakis et al. | Pulmonary endometriosis in a patient with unicornuate uterus and noncommunicating rudimentary horn | |
| Ammar et al. | Effect of oral Tadalafil on endometrial thickness in patients receiving Clomiphene citrate for ovulation induction | |
| Chantraine et al. | Expulsion of a uterine myoma in a patient treated with ulipristal acetate | |
| Aboulghar et al. | Prospective randomized study for hydrotubation versus no hydrotubation before intrauterine insemination in unexplained infertility | |
| Hurst et al. | Endometriosis: pathophysiology, diagnosis, and treatment | |
| Doyle et al. | Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome with a single septate uterus: a novel anomaly and description of treatment options | |
| Tiwari et al. | A comparative study to evaluate diagnostic accuracy and correlation between saline infusion sonography, hysterosalpingography and diagnostic hysterolaparoscopy in infertility | |
| Chaudhry et al. | Perimenopausal vaginal bleeding: diagnostic evaluation and therapeutic options |